On November 15, 2021 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that John P. Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, which takes place November 16 – 19, 2021 (Press release, Akebia, NOV 15, 2021, View Source/news-releases/news-release-details/akebia-therapeutics-present-jefferies-london-healthcare" target="_blank" title="View Source/news-releases/news-release-details/akebia-therapeutics-present-jefferies-london-healthcare" rel="nofollow">View Source [SID1234595634]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The on-demand presentation will be available beginning at 8:00 a.m. GMT on November 18 through the conference site. The webcast will also be available through the Investors section of the Company’s website at View Source for approximately 30 days following the conference.

On November 15, 2021 Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported that its management team will present at the following healthcare conferences (Press release, Savara, NOV 15, 2021, View Source [SID1234595632]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 33rd Annual Virtual Healthcare Conference: A pre-recorded webcast of the presentation will be available beginning at 10:00 AM ET / 7:00 AM PT on November 22, 2021.
Evercore ISI 4th Annual HealthCONx Virtual Conference: A live webcast of a fireside chat will take place at 8:50 AM ET / 5:50 AM PT on November 30, 2021.
Both webcasts will be available through the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

On November 15, 2021 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that members of the senior management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, taking place on Monday, November 29 – Thursday, December 2, 2021 (Press release, Leap Therapeutics, NOV 15, 2021, View Source [SID1234595631]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A replay of the pre-recorded fireside chat can be accessed on Monday, November 22, 2021 at 10:00 a.m. eastern time on the Investors page of the company’s website at View Source, where a replay of the event will also be available for a limited time.

On November 15, 2021 Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, reported the publication of a scientific paper in the peer-reviewed international scientific journal, ACS Pharmacology & Translational Science (Press release, Oryzon, NOV 15, 2021, View Source [SID1234595630]). The article reports a comprehensive comparison of iadademstat, the first LSD1 inhibitor to be developed in the clinic, with most of the LSD1 inhibitors in development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The manuscript, entitled "Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology", compares iadademstat with four LSD1 inhibitors in clinical development in oncology and with five commonly used compounds used in the academia as tool LSD1 inhibitors. Results show that iadademstat is consistently the most active compound across diverse cancer cell lines, that its capability to bind the target is superior, specially at low concentrations, and that the disruption of the transcriptional complexes implicated in the oncogenic programs is more efficacious in the case of iadademstat.

Dr. Jordi Xaus, Oryzon’s CSO, commented: "This set of head-to-head controlled comparisons have shown that iadademstat is clearly the most potent and selective LSD1 inhibitor among all tested clinical molecules. This correlates with the need for lower doses in the clinic, which greatly reduces the potential for idiosyncratic toxicity. A relevant result in this study is that at lower concentrations iadademstat is, by far, the most efficacious in binding LSD1. This may have clinical relevance in solid, dense and poorly vascularized tumors, where the access of drugs to tumoral cells is often an issue".

The paper has been published in the journal ACS Pharmacology & Translational Science as part of the special issue Epigenetics 2022 and is already accessible on-line. The paper can be accessed here: View Source

On November 15, 2021 IKENA Oncology (IKENA; Boston, MA, USA) reported that an investigator-initiated trial of IK-007 (AskAt’s EP4 antagonist AAT-007) in metastatic inflammatory breast cancer was launched in September 2021, led by Naoto Ueno, M.D., of the University of Texas MD Anderson Cancer Center(Press release, AskAt, NOV 15, 2021, View Source [SID1234595538]). The company made this announcement in its Third Quarter 2021 financial results and corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!